• Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon
  • FDA Asked to Approve Darzalex Triple Combo for Relapsed or Refractory Multiple Myeloma
  • Antibiotics Prevent Fevers, Death in Newly Diagnosed Myeloma Patients, Study Says
  • Advancing Novel Cell Therapy for Myeloma and Multiple Cancers Goal of New Partnership
  • EMA Reviewing Belantamab Mafodotin for Heavily Pretreated Multiple Myeloma
  • Takeda, Snow Myeloma App ‘Being Patient’ Wins Pharma Choice Award
  • Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple Myeloma
  • Allogene, SpringWorks Collaborate to Test ALLO-715, Nirogacestat Combo for RRMM
  • Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
  • FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma
  • Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients
  • NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients